Filing Flows › Vanda Pharmaceuticals (VNDA) › Guidance & outlook
Vanda Pharmaceuticals (VNDA) guidance and outlook
Vanda Pharmaceuticals (VNDA) updated its guidance on Oct 28, 2026: Revenue (segment) $240M for FY2026.
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | $240M | new |
From the earnings release filed Oct 28, 2026 (8-K on EDGAR).
Vanda Pharmaceuticals' latest quarter
Vanda Pharmaceuticals, Q3 2026: revenue $69.8M (+24% year over year), operating margin -33.7%, net loss $22.6M, operating cash flow −$28.4M. The chart follows the revenue to costs, profit and cash.
Questions
Did Vanda Pharmaceuticals raise or lower its guidance?
Vanda Pharmaceuticals (VNDA) updated its guidance on Oct 28, 2026: Revenue (segment) $240M for FY2026.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.